SEARCH

SEARCH BY CITATION

References

  • 1
    Cacabelos R. Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 2001;1:158188.
  • 2
    Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E and Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1176.
  • 3
    Cacabelos R, Alvarez XA, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: From phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000;36:415499.
  • 4
    Cacabelos R. Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 2005;27(Suppl A):1573.
  • 5
    http://www.ncbi.nlm.nih.gov/OMIM [Assessed 3 March 2010.
  • 6
    http://www.alzgene.org [Assessed 3 March 2010.
  • 7
    Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002;3:6799.
  • 8
    Suh, Y-H, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: Molecular pahogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 2002;54:469525.
  • 9
    Cacabelos R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiat Dis Treat 2007;3:303333.
  • 10
    Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer's disease. Nat Genet 2007;39:168177.
  • 11
    Meng Y, Lee JH, Cheng R, et al. Association between SORL1 and Alzheimer disease in a genome-wide study. Neuroreport 2007;18:17611764.
  • 12
    Shibata N, Ohnuma T, Baba H, et al. Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population. Dement Geriatr Gogn Disord 2008;26:161164.
  • 13
    Wang Y, Rogers PM, Stayrook KR, et al. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol Pharmacol 2008;74:17161721.
  • 14
    Peri A, Serio M. Neuroprotective effects of the Alzheimer's disease gene seladin-1. J Mol Endocrinol 2008;41:251261.
  • 15
    Schaffer BA, Bertram L, Miller BL, et al. Association of GSK3B with Alzheimer's disease and frontotemporal dementia. Arch Neurol 2008;65:13681374.
  • 16
    Hsu WC, Wang HK, Lee LC, et al. Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. J Neural Transm 2008;115:15371543.
  • 17
    Chen Y, Jia L, Wei C, et al. Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease. Brain Res 2008;1233:196202.
  • 18
    Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Aβ levels, and Alzheimer's disease risk. Cell 2008;133:11491161.
  • 19
    Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:10881093.
  • 20
    Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:10941099.
  • 21
    Lin MT, Simon DK, Ahn CH, et al. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Mol Genet 2002;11:133145.
  • 22
    Cacabelos R. Pharmacogenomics in Alzheimer's disease. Meth Mol Biol 2008;448:213357.
  • 23
    Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 2006;31(Suppl B):5146.
  • 24
    Cacabelos R. Pharmacogenomic biomarkers in neuropsychiatry: The path to personalized medicine in mental disorders. In: Ritsner MS, editor. The handbook of neuropsychiatric biomarkers, endophenotypes and genes, Vol. 4. Netherlands: Springer, 2009; 363.
  • 25
    Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diag 2009;9:567611.
  • 26
    Berry N, Jobanputra V, Pal H. Molecular genetics of schizophrenia: A critical review. J Psychiatry Neurosci 2003;28:415429.
  • 27
    Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007;61:319.
  • 28
    Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002;34:357379.
  • 29
    Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003;4:597621.
  • 30
    Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 2005;6:19671987.
  • 31
    Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 2005;1:303348.
  • 32
    Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res 2003;25:567580.
  • 33
    Mastrangelo MA, Bowers WJ. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 2008;9:81.
  • 34
    Rodríguez JJ, Jones VC, Tabuchi M, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic Mouse model of Alzheimer's disease. PLoS ONE 2008;3:e2935.
  • 35
    Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev Genet 2004;5:645656.
  • 36
    Cacabelos R. Pharmacogenomics and therapeutic prospect in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 1):2847.
  • 37
    Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol Diag Ther 2007;11:385405.
  • 38
    Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4:479500.
  • 39
    Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer's disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol 2007;29(Suppl B):191.
  • 40
    Cacabelos R, Fernández-Novoa L, Pichel V, et al. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Takeda M, Tanaka T, Cacabelos R, editors. Molecular neurobiology of alzheimer disease and related disorders. Basel : Karger, 2004; 94107.
  • 41
    Cacabelos R. Pharmacogenomics in Alzheimer's disease. In: Cohen N, editor. Pharmacogenomics and personalized medicine. NJ : Humana Press, 2008; 317368.
  • 42
    Thomann PA, Roth AS, Dos Santos V, et al. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:300305.
  • 43
    Sando SB, Melquist S, Cannon A, et al. APOEɛ4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway. BMC Neurology 2008. doi:10.1186/1471-2377-8-9.
  • 44
    Giacobini E. Cholinesterases in human brain: The effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: Giacobini E, Pepeu G, editors. The brain cholinergic system in health and disease. Oxon : Informa Healthcare, 2006; 235264.
  • 45
    Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med2003;348:13331341.
  • 46
    Schenk DB, Seubert P, Grundman M, et al. Aβ immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2005;2:255260.
  • 47
    Verrils NM. Clinical proteomics: Present and future prospects. Clin Biochem Rev 2006;27:99116.
  • 48
    Cacabelos R, editor. World guide for drug use and pharmacogenomics. Coruña , Spain : EuroEspes Publishing, 2010, (In Press).
  • 49
    http://www.cypalleles.ki.se [Assessed 3 March 2010.
  • 50
    http://www.pharmgkb.org [Assessed 3 March 2010.
  • 51
    Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokin 2004;19:8395.
  • 52
    Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284295.
  • 53
    Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet 2006;7:223245.
  • 54
    Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009;73:761767.
  • 55
    Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:12711294.
  • 56
    Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology 2009;34:617.
  • 57
    Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7:1028.
  • 58
    Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246254.
  • 59
    Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002;30:553563.